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Abstract
Pyoderma  gangrenosum  is  a  non-infectious  neutro  -
philic skin disease commonly associated with underly-
ing systemic diseases. Histopathological and laboratory
diagnostics are unspecific in the majority of the cases
and the diagnosis is made in accordance with the clini-
cal picture. Here, we report the case of a 69-year old
man with progredient pyoderma gangrenosum-like ul-
cerations under treatment with sunitinib due to hepa-
tocellular carcinoma. a conventional ulcer therapy did
not lead to a regression of the lesions. Solely cessation
of  sunitinib  therapy  resulted  in  an  improvement  of
the ulcerations. Sunitinib is a multikinase inhibitor that
targets  the  PdGF-ʱ-  and  –b-,  VEGF-1-3-,  kIt-,
Flt3-, cSF-1- and REt-receptor, thereby impairing
tumour  proliferation,  pathological  angiogenesis  and
metastasation.  Here,  we  demonstrate  that  pyoderma
gangrenosum-like ulcers may represent a serious side
effect of sunitinib-based anti-cancer treatment.
IntRoductIon
Pyoderma gangrenosum (PG) is a non-infectious neu-
trophilic  dermatosis  and  is  often  associated  with  an
underlying  systemic  disease  [5].  diagnostic  findings
are unspecific in the majority of the cases and the di-
agnosis is made in accordance with the clinical picture.
often the inflammatory process is initiated by unspe-
cific mechanical trauma.
Here, we report a case of PG like ulcerations under
treatment with sunitinib.
caSE REPoRt
a 69-year old man presented to our outpatient clinic
with therapy refractory ulcerations of the right lower
leg,  which  had  been  progredient  over  the  last  4
months (Fig. 1). at the initial presentation we noticed
multiple ulcerations (appr. 2 x 2 to 4 x 6 cmﾲ), hyper-
ceratotical plaques as well as serous to purulent crusts.
Moreover, the patient exposed clinical signs of chron-
ic venous insufficiency, such as purpura jeaune d’ocre,
corona phlebectatica paraplantaris and edema.
comorbities included a metastasized hepatocellular
carcinoma (Hcc; inital diagnosis in 2007; pulmonary
and adrenal metastases), an associated hepatitis c, he-
patic cirrhosis (cHIld a), hypothyreosis, arterial hy-
pertonia and benign hyperplasia of the prostate gland.  
the further patients medical history included a ra-
diation of adrenal gland for metastases of the Hcc
two years ago, multiple transarterial chemoembolisa-
tions  one  year  ago,  palliative  chemotherapies  with
gemcitabine  and  bevacizumab    (for  5  months)  two
years  ago  and  a  therapy  with  sorafenib  until  four
months before presentation in our clinic. at the initial
presentation the patient had been receiving a palliative
chemotherapy with sunitinib (37.5 mg/day p.o.).
differential diagnoses for the ulcerations included
arterial and venous ulcerations, PG, vasculitic ulcera-
tions and traumatic or drug-related ulcerations.  yet,
the characteristic signs of chronic venous insufficiency
suggested  chronical  venous  ulcerations  as  the  most
likely diagnosis. 
accordingly, we initiated a conventional ulcer thera-
py including topical antiseptic measures (octenidin so-
lution), mometasonfuroat ointment for the area sur-
rounding the ulcers, enzymatic debridement and foam
dressings,  as  well  as  intermittant  curretage  of  fibri-
nous coatings combined with compression therapy for
a period of four months. However, these measures did
not result in an improvement of the lesions. converse-
ly, the ulcerations showed a progress in size up to a
maximum wound area of approximately 25 x 30 cmﾲ.
Moreover, new ulcerations developed on the left lower
leg (approx. 2 x 2 cmﾲ).
diagnostic  procedures  included  serological  and
hematological tests (hemoglobin 8.9 g/dl, leucocytes
2300/ﾵl, thrombocytes 152000/ﾵl, Got 68 u/l, GPt
49 u/l, GGt 74 u/l, cRP 0,9 mg/dl, creatinine 0.8
mg/dl, aFP 1965 ﾵg/l, ca19-9 29.2 u/ml, panca
and canca negativ), microbiological swabs, which re-
vealed a generous amount of klebsiella oxytoca, epi-
cutaneous testing (including ointments and dressings,
preservative  agents,  disinfectants,  stabilizers,  antioxi-
dants  and  the  european  standard)  and    abdominal
sonography, which showed hepatic cirrhosis, hepato-
cellular  carcinoma  lesions  without  progress  at  that
time, splenomegalia, a metastasis of the adrenal gland
and an enlarged prostate gland. doppler ultrasound of
both legs showed no significant insufficiency of veins.
because  of  serological  (elevating  cRP)  and  clinical
signs  of  infection  of  the  ulcerations  we  initiated  a
therapy with piperacillin plus combactam i.v., in accor-
dance with the resistogramme. concomitantly erythro-
cyte were given several times due to anemia (hemoglo-
bin < 7g/dl). 
next, we sought to perform vacuum assisted thera-
py to improve wound granulation and reduce bacterial
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Fig. 1. Exsisting ulceration since four months of the right lower leg.
Fig. 2. Progress in size and new purpuric lesions after vacuum assisted therapy.
Fig. 3a-c. (a) one month, (b) two months, (c) six months after stopping treatment with sunitinib.
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three  days  of  vacuum  therapy  ulcerations  showed  a
rapid progress in size and the development of addi-
tional  purpuric  lesions  surrounding  the  ulcerations
along with a livid undermining of the ulcer-borders
was noticed (Fig. 2).
Subsequently performed histopathological examina-
tions were unspecific and showed a compact corneal
layer, unregularly broadened epithelia with hypergran-
ulosis, dilated  blood vessels in corium with on the one
hand perivascular on the other hand interstitial infiltra-
tion consisting of lymphocytes and histiocytes and de-
position of hemosiderin.
based on the characteristic morphological signs, the
histopathologic  examination  and  the  induction  by
minimal trauma the diagnosis of PG-like ulcerations
was made. Moreover, the timely correlation of the be-
ginning of ulcerations and the initiation of sunitinib
therapy  suggested  a  causal  mechanism.  therefore,
sunitinib  was  stopped  in  accordance  with  the  gas-
troenterological departement. one month after stop-
ping administration of sunitinib sorafenib therapy was
initiated. 
In addition, we performed a topical therapy, includ-
ing  desinfection  with  polyhexanide,  0.1%  tacrolimus
ointment,  foam  dressings  and  compression  therapy
[12]. 
under the above mentioned treatment ulcerations
progrediently  improved.  Six  months  after  stopping
treatment with sunitinib a nearly complete healing of
the ulcerations was observed (Fig. 3a-c).
dIScuSSIon
PG is a non-infectious neutrophilic dermatosis that is
characterized  by  pustulations  that  progress  into
painful  ulcerations.  yet,  the  diagnosis  is  challenging
and regarded a diagnosis of exclusion. notably, PG is
commonly initiated or aggravated by unspecific trau-
ma. accordingly, in our case vacuum assisted therapy
and surgical debridement resulted in disease progres-
sion. PG is commonly associated with inflammatory
bowel diseases, autoimmune diseases or malignancies
[13].  therapy  includes  treatment  of  underlying  sys-
temic disease and if not contraindicated systemic im-
munosuppressive  treatment  with  e.g.  glucocorticos-
teroids or cyclosporine.
Sunitinib is a multikinase-inhibitor, which inhibits
the PdGF-ʱ- and –b-, VEGF-1-3-, kIt-, Flt3, cSF-
1- and REt-receptor, thereby impairing tumour prolif-
eration, pathological angiogenesis and metastazation.
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Fig. 4. Hyperpigmentation of the skin.
Fig. 5. Facial erythema and hypopigmentation of hair.
4) Akanay-Diesel##_Umbruchvorlage  12.10.11  12:55  Seite 493Sunitinib is used in the treatment of various tumor en-
tities, such as metastasized renal cell carcinoma, gas-
trointestinal stroma tumour or Hcc [14]. known side
effects of sunitinib include fatigue, diarrhoea, arterial
hypertension,  hypothyreosis  and  also  cutaneous  side
effects like stomatitis, hypo- and hyperpigmentation,
erythrodysesthesia palmoplantaris, facial edema, sub-
ungual hemorrhagia, facial erythema, alopecia and py-
oderma gangrenosum-like ulcerations. In our patient
we observed hyperpigmentation of the skin (Fig. 4),
hypopigmentation of the hair as well as facial erythe-
ma (Fig. 5).
With regard to PG in our patient we could observe
a  rapid  improvement  of  ulcerations  after  stopping
treatment  with  sunitinib.  In  fact,  we  noticed  an  im-
provement of 80% in the first 3 months and a com-
plete healing after 12 months (Fig 3c). 
today  the  cellular  and  molecular  mechanism  of
PG-like  ulcerations  due  to  sunitinib  have  remained
largely elusive but it has been suggested that the an-
tiangiogenic effects of sunitinib by c-kIt- and VEG-
FR-inhibition induce necrosis and the subsequent in-
vasion  of  neutrophilic  granulocytes,  hence  initiating
PG. Interestingly, also other tyrosine-kinase-inhibitors
such as imatinib or erlotinib have been associated to
neutrophilic dermatoses, such as  sweet syndrome or
papulopustular rash, suggesting common mechanisms
[9, 10, 11].
In summary, we here report a rare case of PG-like
ulcerations due to sunitinib-based anti-cancer treatment
and highlight probable management options. Further
studies are needed to determine the exact mechanisms
of sunitinib-associated adverse effects. [1, 2].
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